Cycle Pharmaceuticals Launches CAVHANZA, a PPI-Compatible Nilotinib Formulation
Event summary
- Cycle Pharmaceuticals launched CAVHANZA (nilotinib) Orally Disintegrating Tablets (ODT) in the U.S. on August 24, 2026.
- CAVHANZA is the first FDA-approved ODT formulation of nilotinib, designed for use with PPIs and H₂RAs without food restrictions.
- The product offers a 60% lower milligram strength than Tasigna® (nilotinib) while maintaining established efficacy.
- CAVHANZA is the 10th product in Cycle's portfolio and the 2nd treatment for Ph+ CML.
The big picture
Cycle Pharmaceuticals' launch of CAVHANZA addresses a critical unmet need in the nilotinib market by offering a formulation compatible with acid-reducing agents, a common challenge for patients with Ph+ CML. This move positions Cycle to compete more directly with Novartis' Tasigna, leveraging Flex Pharma's ElectroNanoSpray™ technology to enhance drug performance. The strategic focus on patient-centric formulations aligns with broader industry trends toward improving treatment adherence and outcomes in rare diseases.
What we're watching
- Market Differentiation
- Whether CAVHANZA's PPI compatibility and simplified administration can capture market share from established nilotinib treatments.
- Regulatory Compliance
- The pace at which Cycle can navigate potential regulatory hurdles related to QT prolongation and other safety concerns.
- Patient Adoption
- How the flexibility of CAVHANZA's dosing will impact patient adherence and treatment outcomes in Ph+ CML.
Related topics